DOCKET NO.: CP185B Application No.: 10/718,077 Notice of Allowance dated: January 14, 2010

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

 (Currently amended) A composition comprising a fused pyrrolocarbazole with the formula:

at least about 20% (w/w) of a polyoxyl stearate; and at least one polyethylene glycol.

- (Original) The composition of claim 1 wherein the fused pyrrolocarbazole is present at a concentration of about 1 to about 100 mg/mL.
- (Original) The composition of claim 2 wherein the fused pyrrolocarbazole is present at a concentration of about 1 to about 50 mg/mL.
- (Canceled)
- (Canceled)

Notice of Allowance dated: January 14, 2010

- (Currently Amended) The composition of claim 1 wherein the polyethylene glycol has a molecular weight from about 300 to about 8000 Daltons.
- (Currently Amended) The composition of claim 6 wherein the polyethylene glycol
 has a molecular weight from about 400 to <u>about</u> 3350 Daltons.
- (Currently Amended) The composition of claim 7 wherein the polyethylene glycol has a molecular weight from about 400 to <u>about</u> 1500 Daltons.
- (Previously Presented) The composition of claim 1 wherein the polyethylene glycol is selected from PEG-400, PEG-600, PEG-1000, and PEG-1450.
- 10. (Cancelled)
- (Currently Amended) The composition of claim 9 wherein the ratio of polyethylene glycol:polyoxyl stearate ranges from about 50:50 to about 80:20.
- (Currently Amended) The composition of claim 11 wherein the ratio of polyethylene glycol:polyoxyl stearate is <u>about</u> 50:50.
- (Currently Amended) The composition of claim 11 wherein the ratio of polyethylene glycol:polyoxyl stearate is about 80:20.
- (Original) The composition of claim 1 comprising a polyethylene glycol mixture selected from PEG-400/PEG-1000, PEG-400/PEG-1450, PEG-600/PEG-1000, and PEG-600/PEG-1450.

Notice of Allowance dated: January 14, 2010

- (Currently Amended) The composition of claim 14 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is from <u>about</u> 50:50 to <u>about</u> 80:20.
- (Currently Amended) The composition of claim 15 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is <u>about</u> 50:50.
- (Currently Amended) The composition of claim 15 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is <u>about</u> 80:20.
- (Currently Amended) The composition of claim 16 wherein the composition comprises PEG-400:PEG-1000:polyoxyl stearate in a ratio of about 25:25:50.
- (Currently Amended) The composition of claim 16 wherein the composition comprises PEG-400:PEG-1450:polyoxyl stearate in a ratio of <u>about</u> 25:25:50.
- (Currently Amended) The composition of claim 17 wherein the composition comprises PEG-400:PEG-1000:polyoxyl stearate in a ratio of <u>about</u> 40:40:20.
- (Currently Amended) The composition of claim 17 wherein the composition comprises PEG-400:PEG-1450:polyoxyl stearate in a ratio of <u>about</u> 40:40:20.
- (Withdrawn and currently amended) A method of treating a disease or disorder in a
 mammal, comprising administering a composition of elaims claim 1, 12, or 19 to a
 subject in need thereof.
- (Withdrawn) The method of claim 22 wherein the disorder is a neurological disorder.
- 24. (Withdrawn) The method of claim 22 wherein the disorder is cancer.

- 25. (Withdrawn) The method of claim 24 wherein the cancer is prostate cancer.
- (Withdrawn) The method of claim 24 wherein the cancer is acute myelogenous leukemia.

Claims 27 - 46 (Cancelled)

- (New) The composition of claim 9 wherein the polyoxyl stearate is polyoxyethylene
 (40) stearate.
- (New) The composition of claim 15 wherein the polyoxyl stearate is polyoxyethylene
 (40) stearate.